Rat prostaglandin EP3 receptor is highly promiscuous and is the sole prostanoid receptor family member that regulates INS-1 (832/3) cell glucose-stimulated insulin secretion

Harpreet K. Sandhu1,2 | Joshua C. Neuman3,2 | Michael D. Schaid1,3,2 | Sarah E. Davis4 | Kelsey M. Connors1,2 | Romith Challa1,2 | Erin Guthery1,2 | Rachel J. Fenske3,2 | Chinmai Patibandla1,2 | Richard M. Breyer4 | Michelle E. Kimple1,2,3,5

Abstract
Chronic elevations in fatty acid metabolites termed prostaglandins can be found in circulation and in pancreatic islets from mice or humans with diabetes and have been suggested as contributing to the β-cell dysfunction of the disease. Two-series prostaglandins bind to a family of G-protein-coupled receptors, each with different biochemical and pharmacological properties. Prostaglandin E receptor (EP) subfamily agonists and antagonists have been shown to influence β-cell insulin secretion, replication, and/or survival. Here, we define EP3 as the sole prostanoid receptor family member expressed in a rat β-cell-derived line that regulates glucose-stimulated insulin secretion. Several other agonists classically understood as selective for other prostanoid receptor family members also reduce glucose-stimulated insulin secretion, but these effects are only observed at relatively high concentrations, and, using a well-characterized EP3-specific antagonist, are mediated solely by cross-reactivity with rat EP3. Our findings confirm the critical role of EP3 in regulating β-cell function, but are also of general interest, as many agonists supposedly selective for other prostanoid receptor family members are also full and efficacious agonists of EP3. Therefore, care must be taken when interpreting experimental results from cells or cell lines that also express EP3.

KEYWORDS
animal model, beta cell (β-cell), diabetes, G-protein-coupled receptor, heterotrimeric G protein, insulin resistance, insulin secretion, pancreatic islet, prostaglandin, signaling

ABBRIVATIONS: AA, arachidonic acid; T2D, type 2 diabetic
Harpreet K. Sandhu and Joshua C. Neuman, these authors contributed equally to this work.

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
© 2021 The Authors. Pharmacology Research & Perspectives published by John Wiley & Sons Ltd, British Pharmacological Society and American Society for Pharmacology and Experimental Therapeutics.
INTRODUCTION

Prostaglandins are fatty acid metabolites long understood as regulating β-cell function, particularly in the type 2 diabetic (T2D) state.\(^1\)\(^-\)\(^5\) PGD\(_2\), PGE\(_2\), PGF\(_2α\), PGI\(_2\), and thromboxane A\(_2\) (TXA\(_2\)) are the five major prostanoids derived from the essential omega-6 polyunsaturated fatty acid (PUFA) arachidonic acid (AA). Evidence from a number of models suggests these 2-series prostanoids are produced by and modulate β-cell function, but some of these findings are still controversial.\(^2\)\(^-\)\(^6\)\(^-\)\(^12\) PGD\(_2\), PGE\(_2\), PGF\(_2α\), PGI\(_2\), and TXA\(_2\) agonize DP, EP, FP, IP, and TP receptors, respectively.\(^7\) Confounding the study of prostanoid signaling is the fact there are two DP receptor subfamily members, DP1 and DP2 (a.k.a. CRTH2), and four EP receptor family members, EP1, EP2, EP3, and EP4, that widely vary in their G protein coupling parameters, ultimately eliciting diverse biological changes.\(^7\)\(^,\)\(^13\)

We and others have previously described increased PGE\(_2\) production and/or EP3 expression as negatively regulating glucose-stimulated insulin secretion (GSIS) and contributing to the β-cell dysfunction of diabetes.\(^2\)\(^,\)\(^5\)\(^-\)\(^14\)\(^-\)\(^27\) Yet, other work has suggested EP3’s role may be in regulating β-cell proliferation and not function.\(^3\)\(^4\)\(^,\)\(^15\)

Furthermore, other prostanoid receptors besides EP3—including other EP subfamily members—have been identified as playing roles in regulating insulin secretion.\(^6\)\(^,\)\(^8\)\(^-\)\(^12\)\(^,\)\(^25\) Lastly, isolating the effects of GPCRs on β-cell biology is challenging in primary pancreatic islets due to the complex interplay between the multitude of endocrine cell types.

Clonal INS-1 rat insulinoma-derived cell lines display physiologic glucose responsiveness\(^2\)\(^8\) and respond strongly to EP3 antagonists to reduce GSIS.\(^2\)\(^,\)\(^29\)\(^,\)\(^30\) In this study, we employed the INS-1 (832/3) line and prostanoid receptor agonists and antagonists to definitively address these disparities in the literature. Our findings confirm the importance of EP3 in regulating β-cell function and also serve as a cautionary note when interpreting data using prostanoid receptor agonists, even those commonly understood to be selective.

RESEARCH DESIGN AND METHODS

2.1 Antibodies, chemicals, and reagents

PGE\(_2\) (cat. no. P5640), L798,106 (cat. no. L4545), AH23848 (cat. no. A8227), and SC19220 (cat. no. S3065) were purchased from Sigma-Aldrich. SC51089 (cat. no. 3758) was purchased from Tocris. PF-04418948 (cat. no. 15016), L-161,982 (a.k.a. EP\(_A\)) (cat. no. 10011565), cicaprost (cat. no. 16831), U-46619 (cat. no. 16450), PGF\(_2α\) (cat. no. 16010), iloprost (cat. no. 18215), sulprostone (cat. no. 14765), PGD\(_2\) (cat. no. 12010), indomethacin (cat. no. 70270), and the prostaglandin E\(_2\), monoclonal ELISA kit (cat. no. 514010) were purchased from Cayman Chemical. Interleukin-1β (IL-1β) (cat. no. 130-094-053) was purchased from Miltenyi Biotec. Monoclonal insulin/proinsulin (cat. no. 10R-I136a) and the biotin conjugated anti-insulin antibody (cat. no. 61R-I136bBT) were purchased from Fitzgerald. The RNeasy Mini Kit (cat. no. 74106) and RNase-free DNase set (cat. no. 79254) were purchased from Qiagen. The High-Capacity cDNA Reverse Transcription Kit (cat. no. 4368813) was purchased from Applied Biosystems, and FastStart Universal SYBR Green Master mix (cat. no. 0491394001) purchased from Roche. The cell culture medium was RPMI 1640 medium (cat. no. 22400-105) from Gibco. Arachidonic Acid (AA) (cat. no. 10931) was purchased from Sigma. Low-passage INS-1 (832/3) cells were a generous gift of Dr. Christopher Newgard (Duke University, Durham, NC).

2.2 INS-1 cell culture and GSIS assays

INS-1 (832/3) cells (passage 35 or below) were cultured as previously described\(^2\)\(^,\)\(^31\) Prior to GSIS assays with the indicated compounds, cells were plated in 96-well tissue culture-treated plates and cultured for 72 h.\(^31\) Intracellular and secreted insulin concentrations were determined by an in-house insulin ELISA.\(^2\)\(^,\)\(^17\)

2.3 Gene expression analysis

Cultured cells were lysed in Buffer RLT and RNA purified using the RNeasy kit according to the manufacturer’s instructions. Copy DNA was synthesized from purified RNA using the High-Capacity cDNA Reverse Transcription Kit according to the manufacturer’s protocols. Relative gene expression was quantified by PCR with the primers indicated in Table 1 using SYBR green, as previously described.\(^2\)

2.4 INS-1 (832/3) cell fatty incorporation and analysis of PGE\(_2\) production

70% confluent INS-1 (832/3) cells were cultured in a medium containing 1% fatty acid-free BSA with or without the addition of 100 μM AA for an additional 48 h according to a protocol previously described for isolated mouse islets.\(^2\)\(^,\)\(^17\) AA and EPA phospholipid composition was determined by gas chromatography following a Folch lipid extraction and lipid class separation by thin-layer chromatography as described previously.\(^17\)\(^,\)\(^32\)\(^,\)\(^33\) To induce PGE\(_2\) production, cells were cultured an additional 24 h in vehicle or 10 ng/ml IL-1β. A PGE\(_2\) ELISA was performed according to manufacturer’s protocol, as previously described.\(^17\)

2.5 Statistical analysis

Statistical significance was determined using GraphPad Prism v. 9 (GraphPad Software Inc., San Diego, CA). Data are displayed as means ±SEM. A t test or one- or two-way ANOVA was used to identify the p value as specified in each figure legend. Statistical significance was determined as p < 0.05.
| Protein                        | Gene symbol | Primer sequences                        | Species selectivity |
|-------------------------------|-------------|-----------------------------------------|---------------------|
| β-actin                       | Actb        | F: TCAAGATCATTGCTCTCCTGAGC             | Mouse/rat           |
|                               |             | R: TTGCTGATCCACATCCTGCTGGAAG           |                     |
| Prostaglandin EP3 receptor    | Ptger3      | F: AATTCTTCTTAATCGCCGTTTC             |                     |
| (EP3)                         |             | R: TTTAGCTTGTCATCTGATGGAAG            |                     |
| Cyclooxygenase 1              | Ptgs1       | F: TTAGGCCATGGGAGTAGACCTTT            | Rat                 |
| (COX−1) (Ptgs1)               |             | R: CTGTTCTACCGGAACTTGGGTA             |                     |
| Cyclooxygenase 2              | Ptgs2       | F: ACGGTGAAACACTCTAGACAGACA           | Rat                 |
| (COX−2) (Ptgs2)               |             | R: TCTCCACCAGATGACCTGATATT            |                     |
| Prostaglandin E synthase      | Ptges       | F: GGTGGTGATGAGAAGACGCGCA             | Rat                 |
|                               |             | R: AGTACTGGAAGACCTCCAGGTGGA           |                     |
| Prostaglandin E synthase 2    | Ptges2      | F: CCTATCGGTTGAGAGTTGGA               | Rat                 |
|                               |             | R: ATGGAGCTGTGGAAGCTGTG               |                     |
| Prostaglandin E synthase 3    | Ptges3      | F: GGAAGGGCAGGAACTTTATAATGG           | Rat                 |
|                               |             | R: CCCATGTGACCATCATTGCG               |                     |
| Prostaglandin EP1 receptor    | Ptger1      | F: CACAATCTGCCAACCCTGAATGG            | Rat                 |
| (EP1)                         |             | R: CAAGGTTGGTAATCTGAGGGA              |                     |
| Prostaglandin EP2 receptor    | Ptger2      | F: TCCCTGCCATTTCCAATTCTTTG            | Rat                 |
| (EP2)                         |             | R: ACTGGTGCTCAAGGAGTACAA              |                     |
| Prostaglandin EP4 receptor    | Ptger4      | F: GATGGTCATCTACTACCTGACC             | Rat                 |
| (EP4)                         |             | R: TTGTTGAACACTGCGCACG                |                     |
| Prostaglandin DP1 receptor    | Ptgdr1      | F: CCGTGGTCTTCTATGTCG                | Rat                 |
| (DP1)                         |             | R: GGAAATCGACAGAGGAAAGCG               |                     |
| Prostaglandin DP2 receptor    | Ptgdr2      | F: AGGGACTCTCTGTTTGTG                | Rat                 |
| (DP2) (CRTH2)                 |             | R: GTAGGTAAGAAAGGCAGAGAG              |                     |
| Prostaglandin FP receptor     | Ptgfr       | F: TGGCGAAGCTACACTGCTG                | Rat                 |
| (FP)                          |             | R: ACATCGTGTGAGGATAAAAGCC             |                     |
| Prostaglandin IP receptor     | Ptgir       | F: CGAGAGGATGAAAGTTTACCACC             | Rat                 |
| (IP)                          |             | R: GCGTGAACATCCTGAGTCG                |                     |
| Thromboxane receptor          | Tbxα2r      | F: TTTCTGAGCATCTGACATCC               | Rat                 |
| (TP)                          |             | R: CGTGAAGAGGGGTTCAACAC               |                     |
| EP3α                          | Ptger3      | F: CAACCTGAGCCGAGTTTACCTG             | Rat                 |
| (C-terminus: DQLER)           | (CRA_b)     | R: GCTGTGTCGGTGTGTTTAAATGGC            |                     |
| EP3β                          | Ptger3      | F: CAACCTGAGGAGGAGTTTACCTG            | Rat                 |
| (C-terminus: SPREG)           | (CRA_c)     | R: GCTGTGTCGGTGTGTTTAAATGGC            |                     |
| EP3γ                          | Ptger3      | F: CCTCTTCGAAAGTCTGCGCAAAGGT          | Rat                 |
| (C-terminus: VHPGP)           | (CRA_a)     | R: TCTATGACAGAGAGATGCGGCTG            |                     |
| EP3δ                          | Ptger3      | F: CATTGCAAATACCTGCTTCCCGT            | Rat                 |
| (C-terminus: LCFNR)           | (CRA_d)     | R: GTCTCGGTTGTTTAATGCGGAAG            |                     |

Targets are listed by their protein name and gene symbol. Besides Ptger3 encode a single splice variant. The nomenclature for rat EP3 splice variants is as described in the IUPHAR/BPS Guide to Pharmacology v. 2020.5, with the nomenclature for transcript variants indicated under the gene symbol.
2.6  Data availability

All data contained within this manuscript are available upon reasonable request of the corresponding author.

2.7  Ethics statement

Ethical approval is not applicable to the manuscript.

3  RESULTS

3.1  Characterization of prostanoid receptor mRNA expression in INS-1 (832/3) cells

Quantification of the abundance of EP receptors at the protein level suffers from a lack of specific, reliable antibodies, and the abundance of INS-1 (832/3) EP receptors as quantified by PGE$_1$ radioligand binding was below the detection limit of the assay (S. D. and R. M. B.; data not shown). Therefore, in this and previous works,$^{2,17,30,34}$ mRNA expression is used as a surrogate for protein expression. Quantitative PCR (qPCR) primers spanning exon-exon junctions were optimized using a rat kidney cDNA library and used to perform a comprehensive analysis of INS-1 (832/3) prostanoid family receptor expression (See Table 1 for targets and primer sequences). Ptgdr1 (EP1), Ptgdr2 (EP3), Ptgdr4 (EP4), and Tbx2a2r (TP) display linear cDNA dose-dependent amplification of PCR product, with an amplification factor near the ideal of 2.0 (100% efficiency) (Table 2). Ptgdr2 (EP2), Ptgdr1 (DP1), Ptgfr (FP), and Ptgir (IP) do not appear expressed at any significant level. Two sets of exon-spanning Ptgdr2 (DP2) primers amplified PCR product from rat kidney and INS-1 (832/3) cells, but agarose gel electrophoresis of terminal PCR products showed this amplification was primarily nonspecific (data not shown). Using primers selecting a 119 bp region of Exon 1, Ptgdr2 product is amplified only in INS1 (832/3) cDNA samples but not “no reverse transcription” controls (Figure S1). By qPCR, Ptgdr2 mRNA is also amplified in a linear fashion, with cycle times similar to Ptgdr3 at similar cDNA template concentrations (Table 2, right).

3.2  PGE$_2$ may signal exclusively through EP3 to reduce INS-1 (832/3) GSIS.

PGE$_2$ reduces INS-1 (832/3) GSIS in a dose-dependent manner, and the EP3-specific antagonist, L798,106, shifts the PGE$_2$ dose-response curve to the right, increasing the IC$_{50}$ for PGE$_2$ over 100-fold (Figure 1A and B). The EP2-specific antagonist, PF-04418948, has no effect on the PGE$_2$ dose–response, consistent with a lack of receptor expression (Figure 1C). EP1 mRNA is abundant in INS-1 (832/3) cells (Table 1), yet neither of two EP1 antagonists, SC19220 or SC51089, affect the PGE$_2$ dose–response (Figure 1D and E). To further exclude EP1 signaling, we employed iloprost, which is traditionally known as an EP1 (and IP) receptor agonist, but is only a partial agonist of the rat EP1 receptor and a full agonist of the rat EP3 receptor.$^{35}$ Like PGE$_2$, iloprost dose-dependently reduces GSIS, and the EP1-specific antagonist, SC50189, has no effect on its dose–response curve (Figure 1F). EP4 is also expressed in INS-1 (832/3) cells (Table 1), but was similarly excluded from mediating the effect of PGE$_2$ on GSIS via the EP4-specific antagonists AH2384B and L161,982 (Figure 1G and H). Finally, repeating these experiments with the EP3-selective agonist, sulprostone, yielded nearly identical results as with PGE$_2$, with neither SC51089, AH2384B, SC19220, nor L161,982 affecting the sulprostone dose–response (Figure 1I).

3.3  Supraphysiological concentrations of agonists for the other 2-series prostaglandin receptors reduce INS-1 (832/3) GSIS through EP3

There exists significant cross-reactivity among agonists for the prostanoid receptors (see Table 3, which was created using the IUPHAR/BPS Guide to Pharmacology$^{36,37}$ and its associated primary literature$^{35,38-44}$). DP1, FP, and IP mRNA were not detected in INS-1 (832/3) cells at all, but DP (PGD$_2$), FP (PGF$_2$α), and IP (cicaprost)

| Gene       | cDNA (DF) | Ptgdr1 | Ptgdr2 | Ptgdr3 | Ptgdr4 | Ptgdr1 | Ptgdr2 | Ptgfr | Ptgir | Tbx2a2r | cDNA (DF) | Ptgdr2 |
|------------|-----------|--------|--------|--------|--------|--------|--------|-------|-------|--------|-----------|--------|
| 1 (100 ng) | 18.24     | -      | 26.50  | 30.19  | -      | -      | -      | -     | -     | 31.01  | 31.01     |
| 10         | 22.46     | -      | 29.58  | 34.22  | -      | -      | -      | 34.84 | 31.01  |
| 100        | 26.02     | -      | 33.03  | 37.57  | -      | -      | 36.55  | 36.55 | 31.01  |
| 1000       | 28.94     | -      | 36.51  | -      | -      | -      | -      | 36.55 | 31.01  |
| 10000      | 31.74     | -      | -      | -      | -      | -      | -      | 36.55 | 31.01  |
| Amp. Fact. | 1.99      | -      | 1.94   | 1.87   | -      | -      | -      | 1.99  | 2.29   |

Data shown are cycle time ($C_T$) for primers specific for the indicated genes, using 10-fold (left) or 2-fold (right) serial cDNA template dilutions. An amplification factor of 2.0 correlates with 100% efficiency, with amplification factors above 2.0 indicating some degree of nonspecificity. DF, dilution factor.
agonists all reduce INS-1 (832/3) GSIS starting at a concentration of 1 μM: nearly reaching the maximal potency of PGE₂ (~60% reduction in GSIS) at 50–100 μM (Figure 2A–C, filled squares). TP is weakly expressed in INS-1 (832/3) cells, and 100 μM of the TP agonist, U-46619, inhibits GSIS (Figure 2D, filled squares). In all four of these cases, though, L798,106 fully restores INS-1 (832/3) GSIS (Figure 2A–D, filled circles). Although the addition of L798,106 to increasing concentrations of PGE₂ sometimes yields an unusual bell-shaped dose–response curve (see Figure 2B), this effect is not reproducible or statistically significant.

PGE₂ is a full agonist of the mouse DP2 receptor, albeit with ~3000-fold reduced potency as compared to EP3 (Table 3). Therefore, to further exclude DP2 negatively regulating INS-1 (832/3) GSIS, we used indomethacin, a nonselective COX inhibitor that also has a high affinity for DP2 (Table 3 and 43,45–47). Indomethacin has no significant effect on INS-1 (832/3) GSIS at any concentration, and, although it is not statistically significant, the increased mean GSIS with 100 μM indomethacin is absent in L798,106-treated cells (Figure 2E).

3.4 Testing the role of endogenous EP3 signaling in a model of diabetic β-cell dysfunction

In this and previous works, L798,106 alone has no potentiating effect on INS-1 (832/3) GSIS, similar to findings from primary mouse and human islets from non-diabetic donors.²,³ Figure 3A shows a diagram of the enzymes involved in the conversion of AA to PGE₂ with the reactions catalyzed by COX enzymes rate-limiting. Based on previous work by our laboratory and others,¹¹,¹⁷,⁴⁸ we hypothesized INS-1 (832/3) PGE₂ production could be induced by culturing cells AA-enriched medium, followed by treatment with 10 ng/ml IL-1β to mimic the diabetic state, allowing us to quantify the impact of endogenous EP3 signaling in β-cell dysfunction.

Eicosapentaneoic acid (EPA) is the omega-3 PUFA of corresponding chain-length to AA and competes with AA for the same site in plasma membrane phospholipids and downstream synthetic enzymes. INS-1 (832/3) cells cultured in AA-enriched medium have 4-fold higher AA abundance and a 25-fold higher AA:EPA ratio as compared to controls (Figure 3B). Yet, substrate-dependent PGE₂
Published $pK_i$ of selective agonists of the prostanoid receptor family members reveals EP3 as the most promiscuous.

| Agonist | Target | EP1 | EP2 | EP3 | EP4 | DP1 (CRTH2) | FP | IP | TP |
|---------|--------|-----|-----|-----|-----|-------------|----|----|----|
| PGE$_2$ | EP     | 7.7 | 8.2 | 9.0 | 9.0 | 5.0         | 5.4† | 6.9† | bdli† | 3.8 |
| Iloprost | EP1/IP | 7.9† | 5.9 | 7.3 | 6.6 | 5.0         | 4.0† | 4.6 | 7.9 | 4.1 |
| Sulprostone | EP3 | 7.0 | bdli† | 9.1 | 4.4 | bdli† | 4.4† | 6.5 | bdli† | bdli† |
| PGD$_2$ | DP1/2 | 5.2 | 5.3 | 7.4 | 5.9 | 7.1         | 8.2# | 7.5† | bdli† | 4.1† |
| Indomethacin** | DP2 | 6.4 | 6.7 | 6.7 | 6.2 | 5.0         | 6.3† | 8.4† | bdli† | 4.1† |
| PGF$_2\alpha$ | FP | 4.5† | 4.5† | 6.7† | 5.2† | bdli† | bdli† | 7.9† | bdli† | bdli† |
| Cicaprost | IP | 5.2 | 5.1 | 4.8 | 5.6 | 5.0         | 5.5† | 6.3† | 3.6† | 7.4† |
| U46619 | TP | 5.2 | 5.1 | 4.8 | 5.6 | 5.0         | 5.5† | 6.3† | 3.6† | 7.4† |

Traditionally understood targets for the agonists used in this paper are shown on the left, and $pK_i$ values (white) for prostanoid receptor family members were obtained from the IUPHAR/BPS Guide to Pharmacology v. 2020.5 and its associated primary literature. Subnanomolar efficacy is shown in red, with a gradient to green indicating efficacy below the detection limit (bdli). All agonists beside iloprost at the rat EP1 receptor are full agonists, and all values shown are for the rat receptor variant, if available. White boxes indicate no data on the interaction could be found. *, partial agonist for rat EP1 and full agonist for mouse and human EP1. **, primarily characterized as a nonselective COX inhibitor. #, pIC$_{50}$ and not $pK_i$. †, $pK_i$ is average of those of the mouse and human receptor variants. ‡, $pK_i$ is for the human receptor variant.

FIGURE 2  Any effects of DP, FP, IP, and TP receptor agonists on INS-1 (832/3) GSIS are mediated by EP3. (A–E): (A) PGD$_2$, (B) PGF$_2\alpha$, (C) Cicaprost, (D) U-46619; or (E) indomethacin were added in increasing concentrations to INS-1 (832/3) cells (from 1 pM to 50 or 100 µM) in the presence or absence of 20 µM L798,106. Insulin secretion data are expressed relative to that in 16.7 mM glucose. In all panels, data are from $N = 3$–5 independent experiments and represent mean ± SEM. Data were analyzed by two-way ANOVA followed by Holm–Sidak test post hoc to correct for multiple comparisons. *$p < 0.05$; **$p < 0.01$. 
Combined with a visual observation of reduced confluence on the IL-1β by almost 50%, regardless of fatty acid treatment (Figure 4B).

GSIS is with AA enrichment and IL-1β (Figure 4A, right). IL-1β responsiveness to stimulatory glucose, with little-to-no additional effect of 16.7 mM glucose versus 1.7 mM glucose (Figure 4A, right). IL-1β also reduces INS-1 (832/3) insulin content by almost 50%, regardless of fatty acid treatment (Figure 4B).

Combined with a visual observation of reduced confluence on the day of assay (H. K. S., personal observations), these results suggest IL-1β treatment negatively influences INS-1 (832/3) cell viability.

The only condition in which L798,106 enhances INS-1 (832/3) GSIS is with AA enrichment and IL-1β pretreatment (~30% increase vs. 16.7 mM glucose alone) (Figure 4A, grey bars), consistent with enhanced PGE₂ production. 10 nM PGE₂ blunts INS-1 (832/3) GSIS regardless of AA enrichment, and PGE₂ has no further inhibitory effect on GSIS from IL-1β-treated control cells (Figure 4A, stippled bars). Unexpectedly, though, PGE₂ potentiates INS-1 (832/3) GSIS approximately twofold when AA-enriched cells have been pre-treated with IL-1β (Figure 4A, right).

The Ptger3 gene encodes for multiple splice variants differing only in the sequence of their C-terminal tail.² Quantitative PCR with splice-variant specific primers confirms EP3α, EP3β, EP3γ, and EP3δ are all expressed in INS-1 (832/3) cells, with EP3γ seemingly predominant (Figure 4C). With the relative qPCR assay used in this work, the statistical significance of this difference cannot be quantified. Yet, with nearly identical amplification efficiencies (~1.78), a ΔΔCt of >3 suggests EP3γ could be 10-fold enriched versus the other splice variants. Notably, EP3γ has nearly full constitutive activity.²⁷,⁴⁹,⁵⁰ Combined with gene expression analyses, a stimulatory effect of PGE₂ on INS-1 (832/3) GSIS, potentially mediated by Gαs-coupled EP4, may be unmasked in conditions where EP4 expression is upregulated and EP3 signal transduction mechanisms are fully saturated.

### FIGURE 3

Fatty acid incubation and IL-1β treatment to modulate PGE₂ substrate availability and synthetic enzyme expression. (A) Diagram of the steps in the AA-to-PGE₂ synthetic pathway and the enzymes that catalyze them. (B) AA and EPA content of INS-1 (832/3) membrane phospholipid fractions of cells cultured in AA-enriched medium or BSA control. Data are displayed as a percentage of total fatty acids measured (left) or by the ratio of AA to EPA (right). (C) Prostaglandin E₂ (PGE₂) concentrations in medium from BSA or AA cultured cells treated with 10 ng/mL IL-1β or vehicle control. (D) ΔCt, for genes encoding PGE₂ synthetic enzymes (left) or EP receptors (right) versus β-actin (Actb) as determined by qPCR. In all panels, data are from N = 3–4 independent experiments and represent mean ± SEM. In (B) (right), data were compared by unpaired t-test. In (B) (left), (C), and (D), data were compared by two-way ANOVA with Holm–Sidak test post hoc to correct for multiple comparisons. **p < 0.01, ***p < 0.001, and ****p < 0.0001.

Production is only induced with IL-1β treatment (Figure 3C). This is consistent with the effect of IL-1β on upregulating nearly all of the PGE₂ synthetic pathway genes (Figure 3D). AA enrichment alone moderately upregulates Ptges expression (~3.5-fold vs. control, as calculated via the 2ΔΔCt method), but IL-1β induces its expression by ~100-fold (Figure 3D, left). IL-1β also induces the expression of Ptg1 (~2–4-fold), Ptg2 (~10-fold), Ptgs2 (~2-fold), and Ptges3 (~2.5-fold). Of the EP receptor isoforms expressed in INS-1 (832/3) cells, Ptger3 expression is significantly upregulated by IL-1β treatment (~6-fold) (Figure 3D, right). This finding is consistent with previous findings using islets from T2D mouse models.²¹,²² Ptger4 expression is also strongly upregulated by IL-1β treatment (~10-fold), whereas Ptger1 is unaffected.

In the absence of IL-1β treatment, both control and AA-enriched cells have a strong GSIS response that is unaffected by 20 μM L798,106 (Figure 4A, left). IL-1β treatment alone essentially ablates INS-1 (832/3) responsiveness to stimulatory glucose, with little-to-no additional effect of 16.7 mM glucose versus 1.7 mM glucose (Figure 4A, right). IL-1β also reduces INS-1 (832/3) insulin content by almost 50%, regardless of fatty acid treatment (Figure 4B).

Combined with a visual observation of reduced confluence on the day of assay (H. K. S., personal observations), these results suggest IL-1β treatment negatively influences INS-1 (832/3) cell viability.

The only condition in which L798,106 enhances INS-1 (832/3) GSIS is with AA enrichment and IL-1β pretreatment (~30% increase vs. 16.7 mM glucose alone) (Figure 4A, grey bars), consistent with enhanced PGE₂ production.

### 4 | DISCUSSION

Prostanoid production, particularly that of PGE₂, is perturbed in the diabetic state and has long been suggested to actively contribute to
Our work has shown PGE₂ production is enhanced 4–5-fold in islets isolated from T2D mice and confirmed T2D human organ donors as compared to islets from lean and/or nondiabetic controls. PGE₂ is the most abundant natural ligand for the EP receptor subfamily, with Kᵢ values ranging from sub-nanomolar to 20 nM for the rat receptor variants (EP3 = EP4 > EP1 = EP2) (Table 3). As INS-1 (832/3) cells have no response to the competitive EP3 antagonist, L798,106, to potentiate GSIS, their endogenous production of PGE₂ must be inconsequential, as PGE₁, PGE₂, PGE₃, sulprostone, and iloprost all significantly reduce INS-1 cell GSIS, confirming functional EP3 expression (2,29 and Figures 1 and 3).

IL-1β induces EP3 expression and PGE₂ production from HIT-T15 hamster insulinoma cells, β-HC-13 mouse insulinoma cells, and isolated rat and mouse islets, correlating with decreased β-cell dysfunction.⁵⁻⁷,¹⁷⁻²⁷,⁵¹⁻⁵⁴ Our own work has shown PGE₂ production is enhanced 4–5-fold in islets isolated from T2D mice and confirmed T2D human organ donors as compared to islets from lean and/or nondiabetic controls. PGE₂ is the most abundant natural ligand for the EP receptor subfamily, with Kᵢ values ranging from sub-nanomolar to 20 nM for the rat receptor variants (EP3 = EP4 > EP1 = EP2) (Table 3). As INS-1 (832/3) cells have no response to the competitive EP3 antagonist, L798,106, to potentiate GSIS, their endogenous production of PGE₂ must be inconsequential, as PGE₁, PGE₂, PGE₃, sulprostone, and iloprost all significantly reduce INS-1 cell GSIS, confirming functional EP3 expression (2,29 and Figures 1 and 3).

IL-1β induces EP3 expression and PGE₂ production from HIT-T15 hamster insulinoma cells, β-HC-13 mouse insulinoma cells, and isolated rat and mouse islets, correlating with decreased GSIS ameliorated by COX-2 inhibitors. In this work, we chose IL-1β treatment of AA-enriched cells as a test of our hypothesis that elevated PGE₂/EP3 signaling is necessary and sufficient to elicit the β-cell dysfunction of T2D, and, as such, can be reversed by an EP3 antagonist. Our findings of enhanced COX-2 expression (as well as other enzymes in the PGE₂ production pathway) are confirmatory of those of earlier works (11,17,48 and Figure 3). Yet, the GSIS response of IL-1β-treated INS-1 (832/3) cells is completely ablated: an effect L798,106 only weakly ameliorates (Figure 4). Previous work in rat islets showed the GSIS defect after IL-1β treatment is independent of prostaglandins. Based on INS-1 (832/3) EP3 splice variant gene expression, though, an alternative explanation is selective upregulation of a constitutively active EP3 splice variant limits the ability of EP3 agonists or COX inhibitors to restore GSIS.

This profound loss of insulin content of IL-1β-treated INS-1 (832/3) cells associated with a visually apparent reduction in monolayer confluence on the day of assay suggests IL-1β as a potent negative regulator of INS-1 (832/3) cell replication and/or survival. EP3 deletion or an EP3 antagonist both promote mouse islet beta-cell proliferation, and, in mouse islets, EP3γ is specifically coupled to the pertussis toxin-insensitive Gₛₒ subgroup, Gₛ. The impact of IL-1β on rat islet thymidine incorporation is also pertussis toxin-insensitive. Considering the nearly full constitutive activity of EP3γ and its likely enrichment compared to other splice variants, it is possible the IL-1β-mediated effect on INS-1 (832/3) cell viability is not due to a general toxicity, but is specifically mediated by Gₛ-coupled EP3γ. As EP4 agonists promote β-cell survival, it is also possible EP4 expression is upregulated as a compensatory mechanism that ultimately fails. As yet, all these models remain speculative but provide a strong premise for further exploration.

Although PGE₂ is the predominant and most bioactive 2-series prostanoid formed in pancreatic islets, the remaining 2-series prostanoids, PGD₂, PGF₂α, PGI₂, and TXA₂, are also synthesized in the pancreas and may influence β-cell function. Yet, while DP, FP, IP, and TP receptors are expressed in human islets, they have weak-to-no expression in mouse islet or pancreas tissue. This expression pattern holds true in rat INS-1 (832/3) cells, where DP1, FP, and IP mRNA are not detected at all, and TP receptor mRNA is only detected in more concentrated cDNA samples (Table 2). More importantly, lack of receptor mRNA expression correlates with lack of function, as only supraphysiological concentrations of DP, FP, IP, and TP agonists affect GSIS: effects experimentally confirmed as mediated solely by cross-reactivity with EP3 (Figure 2). Notably, the PGD₂/DP axis has recently re-emerged as a key regulator of islet cell function. In fact, human pancreatic DP2 is so highly enriched in the β-cell, DP2 agonists have been proposed as novel PET tracers for determining β-cell mass in vivo. Interestingly, we do find DP2 mRNA is expressed in INS-1 (832/3) cells, but this expression does not correlate with function, as indomethacin has no effect on GSIS. As DP2 mRNA expression was only detected with primers not spanning an exon–exon junction, DP2 mRNA expression may not correlate with protein expression. Using mass spectrometry to detect
full-length DP2 protein in INS-1 (832/3) plasma membrane preparations would confirm proper protein folding and membrane integration. If DP2 is indeed expressed and functional in INS-1 (832/3) cells, its signaling may regulate other aspects of β-cell biology besides insulin secretion (e.g., proliferation or survival).

In sum, we characterized the impact of signaling through the entire prostanoid receptor family, whose native agonists are metabolites of AA, in the functional response of the glucose-responsive INS-1 (832/3) cell line. With the dramatic effect of IL-1β on INS-1 (832/3) insulin content and secretion, we were unable to use this model to confirm EP3 as the sole mediator of PGE2-mediated β-cell dysfunction in the T2D state, although it is certainly a contributor. These same conditions may have uncovered a stimulatory effect of PGE2 on GSIS mediated by EP4, although this hypothesis remains unconfirmed. Fortuitously, the predominance of EP3 in mediating the inhibitory effect of PGE2 on INS-1 (832/3) GSIS allowed us to use this cell line as a model to test the cross-reactivity of prostanoid receptor agonists for EP3, determining many of these agonists nonspecifically activate EP3 with functional consequence. In fact, EP3 is the most promiscuous out of the entire prostanoid receptor family, with $K_i$ values no weaker than 200 nM for 6 of the 7 prostanoid receptor agonists used in this work, even those thought to be relatively specific (e.g., cicaprost and PGF$_2α$) (Table 3). Even more worrisome, EP3 protein is notoriously difficult to detect, with no available binding assay or antibody that detects endogenous protein. These findings have significant implications for the study of prostanoid receptor family members in any cell line or tissue, particularly those in which EP3 expression is known or suspected.

ACKNOWLEDGMENTS

We thank the many present and former members of the Kimple Laboratory who contributed technical assistance or scientific discussion during the course of these experiments. H. K. S., J. C. N., M. D. S., S. E. D., K. M. C., R. C., E. G., R. J. F., C. P., and M. E. K. generated and analyzed the raw data. M. E. K. completed the final data analysis. R. M. B. and M. E. K. supervised the project. H. K. S. and J. C. N. drafted the manuscript. M. E. K. and R. M. B. edited the manuscript and M. E. K. wrote the final version. All authors reviewed and approved the final version of the manuscript. This work was supported in part by Merit Review Award 101 BX003700 from the United States (U.S.) Department of Veterans Affairs Biomedical Laboratory Research and Development Service (BLR&D) (to M. E. K) and I01 BX000616 (to R. J. B). Further support was provided by ADA Grant 1-16-IBS-212 (to M. E. K.), JDRF Grant 17-2011-608 (to M. E. K.), and NIH Grants K01 DK080845 (to M. E. K.), R01 DK102598 (to M. E. K.), F31 DK109698 (to R. J. F.), R56 HL127218 (to R. M. B.), and R01 HL134895 (to R. M. B.). Joshua Neuman was supported in part by a T32 fellowship from the UW Biology of Aging and Age-related Diseases Training Grant (T32 AG000213). The funding bodies had no role in any aspect of the work described in this manuscript. M. E. K. is the guarantor of this work and, as such, had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

DISCLOSURES

H. K. S., M. D. S., S. E. D., K. M. C., R. C., E. G., R. J. F., C. P., R. M. B., and M. E. K. declare that they have no conflicts of interest with the contents of this article. J. C. N is currently a Novo Nordisk Inc. employee (800 Scudders Mill Road, Plainsboro, NJ 08536). This work was completed in full during his predoctoral training with Dr. Kipple and is not related to his current position. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health, the U.S. Department of Veterans Affairs, or the United States Government.

ORCID

Michelle E. Kipple https://orcid.org/0000-0003-0869-9699

REFERENCES

1. Johnson DG, Fujimoto WY, Williams RH. Enhanced release of insulin by prostaglandins in isolated pancreatic islets. Diabetes. 1973;22(9):658-663.
2. Kipple ME, Keller MP, Rabagli MR, et al. Prostaglandin E2 receptor, EP3, is induced in diabetic islets and negatively regulates glucose- and hormone-stimulated insulin secretion. Diabetes. 2013;62(6):1904-1912.
3. Metz S, VanRollins M, Strife R, Fujimoto W, Robertson RP. Lipoxgenase pathway in islet endocrine cells. Oxidative metabolism of arachidonic acid promotes insulin release. J Clin Invest. 1983;71(5):1191-1205.
4. Oshima H, Taketo MM, Oshima M. Destruction of pancreatic β-cells by transgenic induction of prostaglandin E2 in the islets. J Biol Chem. 2006;281(39):29330-29336.
5. Robertson RP. Arachidonic acid metabolite regulation of insulin secretion. Diabetes Metab Rev. 1986;2(3-4):261-296.
6. Akpan JO, Hurley MC, Pek S, Lands WE. The effects of prostaglandins on secretion of glucagon and insulin by the perfused rat pancreas. Can J Biochem. 1979;57(6):540-547.
7. Breyer RM, Bagdassarian CK, Myers SA, Breyer MD. Prostanoid receptors: subtypes and signaling. Annu Rev Pharmacol Toxicol. 2001;41:661-690.
8. Heaney TP, Larksin RG. The effect of prostacyclin and 6-keto-prostaglandin F1 alpha on insulin secretion and cyclic adenosine 3’,5’-monophosphate content in isolated rat islets. Diabetes. 1991;30(10):824-828.
9. Horie H, Narumiya S, Matsuyama T, Nonaka K, Tarui S. Presence of prostaglandin D2, E2 and F2 alpha in rat pancreatic islets. Prostaglandins Leukot Med. 1984;16(1):39-44.
10. Sieradzki J, Wolan H, Szczeklik A. Effects of prostacyclin and its stable analog, iloprost, upon insulin secretion in isolated pancreatic islets. Prostaglandins. 1984;28(3):289-296.
11. Tran PO, Gleason CE, Robertson RP. Inhibition of interleukin-1beta-induced COX-2 and EP3 gene expression by sodium salicylate enhances pancreatic islet β-cell function. Diabetes. 2002;51(6):1772-1778.
12. Turk J, Hughes JH, Easom RA, et al. Arachidonic acid metabolism and insulin secretion by isolated human pancreatic islets. Diabetes. 1988;37(7):992-996.
13. Wettschureck N, Offermanns S. Mammalian G proteins and their cell type specific functions. Physiol Rev. 2005;85(4):1159-1204.
14. Carboneau BA, Allan JA, Townsend SE, Kimple ME, Breyer RM, Gannon M. Opposing effects of prostaglandin E2 receptors EP3 and EP4 on mouse and human β-cell survival and proliferation. Molecular metabolism. 2017;6(6):548-559.
15. Ceddia RP, Lee Daek Kee, Maulis MF, et al. The PGE2 EP3 receptor regulates diet-induced adiposity in male mice. Endocrinology. 2016;157(1):220-232.
10 of 11

17. Neuman JC, Schaid MD, Brill AL, et al. Enriching islet phospholipids with eicosapentaenoic acid reduces prostanoid E2 signaling and enhances diabetic β-cell function. Diabetes. 2017;66(6):1572-1585.

18. McRae JR, Day RP, Metz SA, Halter JB, Ensink JW, Robertson RP. Prostaglandin E2 metabolite levels during diabetic ketoacidosis. Diabetes. 1985;34(8):761-766.

19. McRae JR, Metz SA, Robertson RP. A role for endogenous prostanoids in defective glucose potentiation of nonglucose insulin secretagogues in diabetics. Metabolism. 1981;30(11):1065-1075.

20. Metz SA, McRae JR, Robertson RP. Hypothesis: prostanoids mediate defective glucose recognition in diabetes mellitus. Prostaglandins Med. 1980;4(4):247-254.

21. Metz SA, Meredith M, Vadakekalam J, Rabaglia ME, Kowluru A. A defect late in stimulus-secretion coupling impairs insulin secretion in Goto-Kakizaki diabetic rats. Diabetes. 1999;48(9):1754-1762.

22. Robertson RP. Prostaglandins, glucose homeostasis, and diabetes mellitus. Annu Rev Med. 1983;34:1-12.

23. Robertson RP. Eicosanoids as pluripotential modulators of pancreatic islet function. Diabetes. 1988;37(4):367-370.

24. Robertson RP. Molecular regulation of prostanoid synthesis implications for endocrine systems. Trends Endocrinol Metab. 1995;6(9-10):293-297.

25. Robertson RP. Dominance of cyclooxygenase-2 in the regulation of islet prostanoid synthesis. Diabetes. 1998;47(9):1379-1383.

26. Robertson RP. The COX-2/PGE2/EP3/Gi/o/cAMP/GsIS pathway in the islet: The beat goes on. Diabetes. 2017;66(6):1464-1466.

27. Robertson RP, Chen M, McRae JR, Metz SA. Improvement of insulin secretion in diabetics by a prostaglandin synthesis inhibitor. Adv Exp Med Biol. 1979;119:227-231.

28. Hohmeier HE, Mulder H, Chen G, Henkel-Rieger R, Prentki M, Newgard CB. Insulin secretion in Goto-Kakizaki diabetic rats. Diabetes. 1983;34(8):761-766.

29. Kimple ME, Nixon AB, Kelly P, et al. A role for G(z) in pancreatic islet β-cell biology. J Biol Chem. 2005;280(36):31708-31713.

30. Brill AL, Wisinski JA, Cadena MT, et al. Synergy between galphaz deficiency and GLP-1 analog treatment in preserving functional β-cell mass in experimental diabetes. Mol Endocrinol. 2016;30(5):543-556.

31. Bhutnagar S, Oler AT, Rabaglia ME, et al. Positional cloning of a type 2 diabetes quantitative trait locus; tomosyn-2, a negative regulator of insulin secretion. PLoS Genet. 2011;7(10):e1002323.

32. Flowers MT, Ade L, Strable MS, Ntambi JM. Combined deletion of SCD1 from adipose tissue and liver does not protect mice from obesity. J Lipid Res. 2012;53(8):1646-1653.

33. Miyazaki M, Kim HJ, Man WC, Ntambi JM. Oleoyl-CoA is the major de novo product of stearoyl-CoA desaturase 1 gene isoform and substrate for the biosynthesis of the Harderian gland 1-alkyl-2,3-diacylglycerol. J Biol Chem. 2001;276(42):39455-39461.

34. Fenske RJ, Cadena MT, Harenda QE, et al. The inhibitory G protein alpha-subunit, galphaz, promotes type 1 diabetes-like pathophysiology in NOD mice. Endocrinology. 2017;158(6):1645-1658.

35. Boie Y, Stocco R, Sawyer N, et al. Molecular cloning and characterization of the four rat prostanoid E2 prostanoid receptor subtypes. Eur J Pharmacol. 1997;340(2-3):227-241.

36. Alexander SPM, Christopoulos A, Davenport AP, et al. The concise guide to pharmacology 2019/20: G protein-coupled receptors. Br J Pharmacol. 2019;176(Suppl 1):S21-S141.

37. Breyer RM, Clapp L, Coleman RA, et al. Prostanoid receptors (version 2020.4) in the IUPHAR/BPS guide to pharmacology database. IUPHAR/BPS Guide to Pharmacology CITE. 2020;2020(4): https://doi.org/10.2218/gtopdb/FSB/2020.4.
58. Regard JB, Sato IT, Coughlin SR. Anatomical profiling of G protein-coupled receptor expression. Cell. 2008;135(3):561-571.

59. Davani D, Kumar S, Palaia T, Hall C, Ragolia L. Lipocalin-type prostaglandin D2 synthase reduces glucagon secretion in alpha TC-1 clone 6 cells via the DP1 receptor. Biochem Biophys Rep. 2015;4:224-227.

60. Skrtic S, Tyrberg B, Broberg M, et al. Exploring the insulin secretory properties of the PGD2-GPR44/DP2 axis in vitro and in a randomized phase-1 trial of type 2 diabetes patients. PLoS One. 2018;13(12):e0208998.

61. Jahan M, Johnström P, Selvaraju RK, et al. The development of a GPR44 targeting radioligand [(11)C]AZ12204657 for in vivo assessment of beta cell mass. JNMNI Res. 2018;8(1):113.

62. Eriksson O, Johnström P, Cselenyi Z, et al. In vivo visualization of β-cells by targeting of GPR44. Diabetes. 2018;67(2):182-192.

63. Hellström-Lindahl E, Danielsson A, Ponten F, et al. GPR44 is a pancreatic protein restricted to the human beta cell. Acta Diabetol. 2016;53(3):413-421.

SUPPORTING INFORMATION
Additional supporting information may be found online in the Supporting Information section.

How to cite this article: Sandhu HK, Neuman JC, Schaid MD, et al. Rat prostaglandin EP3 receptor is highly promiscuous and is the sole prostanoid receptor family member that regulates INS-1 (832/3) cell glucose-stimulated insulin secretion. Pharmacol Res Perspect. 2021;9:e00736. https://doi.org/10.1002/prp2.736